| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Leonard E Post is Director at QURE and has filed Form 4s across 3 companies. Leonard E Post's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.0M at current prices.
Historically, Leonard E Post's trades have earned a below-average insider score of 40/100 across 23 rated trades. Over a 12-month horizon, 11.8% of those trades were profitable, with an average 12-month return of -61.2%.
The biggest single holding is QURE (~$847K) as Director. The QURE filings lean toward selling, a net 9,802 shares.
Leonard E Post has 35 Form 4 filings on record from September 2020 to October 2026, across 3 companies: Director at CG Oncology (CGON), 2024–2026; Director at uniQure (QURE), 2020–2026; Director at Fulgent Genetics (FLGT), 2022.
The 67 reported transactions were 28 open-market sales, 20 option exercises, 11 option or other derivative awards and 8 stock awards.
Counted by filing, the open-market trades come to no purchases and 26 sales worth about $1.8M.
The largest open-market sale was 5,000 shares of CGON at an average $70.00 on June 24, 2026, about $350K.
20 of the 24 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 4 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | CGON Cg Oncology, Inc. | Director | Sale+OE10b5-1 | 1,000 | $62.07 | $62,065.00 | - | - | - | |
| Sep 15, 2026 | CGON Cg Oncology, Inc. | Director | Sale+OE10b5-1 | 1,000 | $72.98 | $72,980.00 | - | - | - | |
| Aug 14, 2026 | CGON Cg Oncology, Inc. | Director | Sale+OE10b5-1 | 1,000 | $74.54 | $74,540.00 | - | - | - | |
| Jul 15, 2026 | CGON Cg Oncology, Inc. | Director | Sale+OE10b5-1 | 1,000 | $71.17 | $71,170.00 | - | -14.5% | - | |
| Jun 24, 2026 | CGON Cg Oncology, Inc. | Director | Sale+OE10b5-1 | 5,000 | $70.00 | $350,000.00 | - | +13.1% | - | |
| Jun 22, 2026 | CGON Cg Oncology, Inc. | Director | Sale+OE10b5-1 | 5,000 | $65.00 | $325,000.00 | - | +18.1% | - | |
| Jun 11, 2026 | QURE Uniqure N.V. | Director | Sell | 1,993 | $27.06 | $53,930.58 | -5.3% | +71.5% | - | |
| Jun 4, 2026 | CGON Cg Oncology, Inc. | Director | Sale+OE10b5-1 | 1,000 | $54.50 | $54,500.00 | - | +33.0% | - | |
| Nov 17, 2025 | CGON Cg Oncology, Inc. | Director | Sale+OE10b5-1 | 1,000 | $41.43 | $41,430.00 | - | +30.6% | - | |
| Oct 13, 2025 | CGON Cg Oncology, Inc. | Director | Sale+OE10b5-1 | 1,000 | $43.25 | $43,250.00 | - | +25.0% | +45.3% |